European targets called for reductions in infections caused by two common bacteria, but both trends went in the opposite direction. The clearest gap was for Klebsiella pneumoniae, a bacterium common in hospitals: infections rose by an estimated 72 per cent from 2019 to 2025, against a target reduction of five per cent.

The World Health Organization (WHO) and the European Centre for Disease Prevention and Control issued a joint alert after reviewing progress against targets for resistant infections in healthcare settings. For E. coli infections resistant to a group of antibiotics called cephalosporins, the aim was a 10 per cent reduction. The increase instead exceeded 16 per cent.

Fewer drugs to turn to in hospital

In roughly half of European countries, WHO found that at least half the samples of Klebsiella pneumoniae and another bacterium, Acinetobacter, showed resistance to key antibiotics. Dr Marc-Alain Widdowson, head of health security at WHO/Europe, said doctors in many countries in the region could no longer rely on their usual first choice of antibiotic for serious hospital infections.

If the initial treatment fails, doctors turn to carbapenems, stronger antibiotics generally reserved for the most serious cases, Widdowson said. If those drugs also fail, the alternatives are mostly last-resort medicines. There are few of them, they are often costly and not all countries have access to them. Widdowson said patients face a higher risk of dying in hospital if the first antibiotic they receive is ineffective against their infection.

What blood testing can tell doctors and countries

WHO identified a difficulty that arises even before a doctor chooses the first drug. In hospitals that take few blood samples to identify the bacterium responsible for an infection, doctors often have little basis for deciding which antibiotic will work. WHO said better testing could shorten the wait for an effective treatment.

The same information matters beyond the hospital. Without dependable data, national health authorities cannot tell where resistance is spreading or assess the measures they have taken to curb it, WHO said. Coordination is another gap: 16 of the 51 countries reviewed still lacked both national coordination and a standardised national approach.

One measure improved despite the high proportion of Acinetobacter samples showing resistance in many countries. WHO estimated that the rate of bloodstream infections caused by resistant Acinetobacter had fallen to little more than half its high level in 2021, during the COVID-19 pandemic.